ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LCTX vs IPSC // GROSS PROFIT MARGIN

Lineage Cell Therapeutics Inc. (NYSE) VS. Century Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LCTX 1 — IPSC 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LCTX VS. IPSC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LCTX IPSC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -14.10% -20.90 IPSC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.46% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -15.80% -44.20 IPSC /operating-margins <GO>
Net Profit Margin -60.00% -8.80% -51.20 IPSC /net-margins <GO>
Revenue Growth (YoY) 53.20% 180.00% -126.80 IPSC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.8 44.7 +6.09 LCTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.5M $264.4M -$3.9M IPSC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LCTX REV IPSC REV LCTX GROSS % IPSC GROSS % LCTX FCF IPSC FCF
FY 2025 $14.6M $109.2M — — -$19.4M -$104.7M
FY 2024 $9.5M $6.6M 96.5% — -$23.7M -$110.3M
FY 2023 $8.9M $2.2M — — -$28.6M -$88.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LCTX // BETA —
IPSC // BETA —